Stephens Lowers Phreesia (NYSE:PHR) Price Target to $20.00

Phreesia (NYSE:PHR) had its price target decreased by equities researchers at Stephens from $32.00 to $20.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Stephens’ price objective indicates a potential upside of 137.56% from the stock’s current price.

PHR has been the subject of several other research reports. Royal Bank Of Canada started coverage on shares of Phreesia in a research note on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price target for the company. Canaccord Genuity Group decreased their price target on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating for the company in a research report on Tuesday. Zacks Research downgraded shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Wall Street Zen lowered Phreesia from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 8th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday. Thirteen equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Phreesia Stock Performance

PHR opened at $8.42 on Tuesday. The company’s 50 day moving average is $12.51 and its 200 day moving average is $17.68. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a market cap of $507.58 million, a price-to-earnings ratio of -81.54 and a beta of 0.67. Phreesia has a 12-month low of $8.00 and a 12-month high of $32.76.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). The business had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.11) earnings per share. On average, equities research analysts predict that Phreesia will post -1.1 EPS for the current year.

Insider Activity

In other news, CFO Balaji Gandhi sold 8,009 shares of Phreesia stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $136,233.09. Following the transaction, the chief financial officer directly owned 156,231 shares of the company’s stock, valued at $2,657,489.31. The trade was a 4.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $107,452.17. Following the sale, the insider directly owned 834,632 shares of the company’s stock, valued at approximately $14,197,090.32. The trade was a 0.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 70,358 shares of company stock worth $1,123,569. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Phreesia by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company’s stock valued at $97,194,000 after purchasing an additional 39,540 shares during the period. Greenhouse Funds LLLP raised its position in shares of Phreesia by 16.8% during the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after purchasing an additional 557,265 shares during the period. Granahan Investment Management LLC lifted its holdings in shares of Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after purchasing an additional 1,018,987 shares during the last quarter. Franklin Resources Inc. grew its position in Phreesia by 28.8% during the 4th quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock worth $33,841,000 after purchasing an additional 446,890 shares in the last quarter. Finally, Nuveen LLC lifted its holdings in shares of Phreesia by 12.7% in the fourth quarter. Nuveen LLC now owns 1,875,725 shares of the company’s stock valued at $31,737,000 after purchasing an additional 211,262 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Phreesia News Summary

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Several brokers kept buy/outperform stances or price targets above the current level, implying upside and supporting a rebound: BMO kept an “outperform” rating with a $14 target. Benzinga
• Positive Sentiment: Canaccord Genuity reiterated a “buy” rating despite lowering its target to $22, signaling confidence in longer-term upside. Benzinga
• Positive Sentiment: Needham kept a “buy” rating while cutting its target to $14, another vote that some analysts view the stock as attractive after the pullback. Benzinga
• Neutral Sentiment: Company results: Q4 revenue of about $127M (+15.9% YoY) and fiscal-year operating/cash-flow milestones were reported, but quarter-level EPS and metric headlines were mixed across sources (some headline misses, some call transcripts indicating beats), leaving clarity for investors dependent on the call/slide details. Press Release / Slide Deck
• Negative Sentiment: Management cut FY2027 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the earlier steep share decline. Benzinga Guide Cut Article
• Negative Sentiment: Multiple analysts downgraded or cut price targets after the guidance cut — Robert W. Baird and Citigroup reaffirmed neutral/hold views with $10 targets, and Truist held at $11 — increasing near-term selling pressure and lowering consensus valuation expectations. TickerReport
• Negative Sentiment: Market reaction: headlines show shares plunged ~22–26% immediately after the results/guidance, indicating heightened short-term risk and potential for continued volatility. MSN

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.